Nucleoside analogs ( NAs ) have been used extensively in both antitumor and antiviral therapies. Their general mechanism of action has been postulated to result from incorporation into DNA, leading to disruption of DNA synthesis and DNA polymerase inhibition. To further explore the antitumor mechanisms of NAs we have evaluated ganciclovir ( GCV ), an NA antiviral agent, in herpes simplex virus thymidine kinase ( HSV -TK ) gene -modified tumor cells. This system allows specific evaluation of the antitumor effects of NAs because the antitumor effect is directly related to the phosphorylation of the prodrug GCV by the HSV -TK enzyme in the genemodified tumor cells. We demonstrated that GCV incorporates into DNA and inhibits DNA polymerase, as has been observed in HSV -infected cells and with other antitumor NAs in tumor cells. A novel observation is that GCV activates MAP kinase within 1 hour of GCV exposure. This activation directly correlates with cytotoxicity, because inhibition of the MAP kinase extracellular regulated kinase ( Erk ) by PD98059, reversed GCV -mediated cytotoxicity. This effect appears to be specific to the Erk pathway, because inhibition of the p38 kinase with SB203580 had no effect on cytotoxicity. Further, GCV does not act as a DNA -damaging agent or activate general DNA -repair mechanisms, but does produce a number of metabolic disruptions, including a reversible decrease in NAD levels. These effects appear to be downstream of the earlier activation of Erk in this system, which may be a novel mechanism of action for GCV cytotoxicity in HSV -TK gene -modified tumor cells, and thus, needs to be further evaluated as the mechanism of tumor cell killing by other antitumor NAs.
N ucleoside analogs (NAs ) have been developed as antitumor agents, and their activity generally has been shown to result from their incorporation into the DNA and /or inhibition of the DNA polymerases of cells. Because tumor cells are rapidly dividing, these agents have a pronounced effect on tumor growth, although the toxicity of the NAs can be observed on other normal dividing cells as well. 1, 2 We have been investigating other mechanisms of cytotoxicity by a model NA, ganciclovir ( GCV ), and demonstrate that its killing may be mediated by an alternate pathway, through MAP kinase, which could potentially be targeted to improve the antitumor activity.
GCV is a derivative of acyclovir, which was developed in the early 1980s to treat herpes simplex virus ( HSV ) infections. 3 Its antiviral mechanism of action is through inhibition of viral polymerases, and DNA chain termination. 4 Unlike acyclovir, GCV has a free 3 0 hydroxyl group and, thus, is not a strict chain terminator. The herpes simplex virus thymidine kinase ( HSV-TK ) system is based on the observation that cells modified with this gene are killed by the antiviral drug GCV. Cells that are either infected with the herpes virus or modified with the HSV-TK gene efficiently monophosporylate GCV. Once monophosporylated, the drug can be di -and triphosphorylated by normal cellular enzymes into a toxic compound that inhibits viral DNA polymerase 5 -7 and leads to tumor cell killing, in the case of tumor cells modified to express only the HSV-TK. 8, 9 The mechanism of antiviral activity may not be related to the antitumor action, and it is necessary to distinguish the inhibitory effects on growth of the virus, which contains all viral genes, including polymerases, from the growth inhibition of genetically modified cells containing only the herpes viral thymidine kinase gene.
We have been investigating potential mechanisms of action of NAs using a single enzyme/substrate model, i.e., HSV-TK gene -modified tumor cells and GCV. Unlike most nucleoside analogs, GCV does not appear to be toxic through DNA damage and repair mechanisms. Our previous studies showed that although IFN significantly increased the toxicity of GCV, it did not enhance the incorporation of GCV into cellular DNA, suggesting that there was no correlation between the amount incorporated and cell killing. 10 Our present studies showed that after removal of GCV from the extracellular medium, no significant amounts of GCV were excised, even in the absence of IFN exposure, suggesting that the repair enzymes did not recognize it as an illegitimate base, and DNA synthesis was not immediately stopped by its presence.
Further studies demonstrate that the MAP kinase cellular signaling pathway is disrupted by GCV, and that this disruption correlates with cytotoxicity. MAP kinases are key regulatory enzymes that are activated in response to many different stimuli and are important in signal transduction. They include Erk 1 /2 Jun kinase, p38 kinase, and ERK5. The extracellular regulated kinase ( Erk ) pathway is comprised of multiple components, organized in a cascade of kinases that begins with the Ras G -protein -coupled receptor that when activated activates a series of MAP kinase kinases ( MAP kinase kinase kinase, MAP kinase kinase, and MEK among others ). Ultimately, the MAP kinases can phosphorylate multiple substrates, particularly transcription factors important for cell growth and cell cycle progression. They can also activate other kinases, which then go on to phosphorylate targets important for cell growth ( reviewed in Ref. 11 ). Thus, an effect on MAP kinase activity can have a profound effect on cell growth.
12,13 MAP kinase activation has been implicated in both cytoprotection and cytotoxicity, depending on the cell type, nature of the agent, and duration of exposure. Erk activation has been correlated with activation -induced cell death in T cells 14 and with hyperoxia -induced cell death in macrophages. 15 In both of these examples, cell death could be prevented by the addition of PD98059, a selective inhibitor of MEK1. In addition, in MCF tumor cells, taxol -induced apoptosis was shown to be dependent on the Erk and p38 pathways 16 whereas induction of activin -induced apoptosis on T47D cells was due to p38 alone. 17 Thus, these pathways appear to have an important role in tumor cell survival and apoptosis.
Our studies show early activation of the Erk pathway by GCV, which may be involved in mediating cell death by GCV in HSV-TK -expressing cells. This activation of the Erk pathway occurs earlier than many other GCV-induced disruptions that may occur secondarily to this primary toxic event. These studies provide novel insight into mechanisms by which nucleoside analogs can disrupt cell function, which may be useful pathways for targeting to enhance the efficiency of this and perhaps other NA therapies. H -labeled GCV for 24 hours, followed by removal of drug and washing. The levels of incorporated GCV were evaluated up to 24 hours after washout. Results of three separate experiments and SD are shown.
Materials and methods

Cell lines and culture conditions
Cancer Gene Therapy nonessential amino acids. DU145 cells are a prostate carcinoma obtained from ATCC; DU145 TK contain the HSV-TK gene, and are maintained under the same conditions. Cells containing the HSV-TK gene are selected for G418 resistance and periodically documented to be free of replication competent retrovirus.
Cytotoxicity assays
Neutral red and colony forming assays were employed to evaluate cytotoxicity of GCV, as previously described. 10 These assays have been validated for this system. Both types of assays were conducted for all studies related to toxicity and were confirmatory. Results are reported only for neutral red assays. PD98059 and SB203580 were obtained from Sigma (St. Louis, MO ) and dissolved in DMSO at 10 mM. For cell culture studies, these stocks were diluted 1:1000, and DMSO alone at 1:1000 had no significant effect on cell viability.
Western analysis
Cells were seeded at ( 1 -2 )Â10 6 cells/150 -cm 2 dish and allowed to adhere. Cells were incubated with agents for varying times, as specified in results, and harvested by adding lysis buffer containing protease inhibitors and scraping with a cell scraper. The DNA was sheared, the lysate centrifuged, and the nucleic acids removed. Protein content was determined by Bradford analysis, and the lysates were stored at À 708C until use. For PARP analysis, anti -PARP antibody ( Upstate Biotech, Lake Placid, NY ) was added (equivalent amounts of protein in each sample ) and samples were rotated at 48C overnight. Samples were then added to 0.1 mL of protein A agarose beads and rotated for 2 hours, then washed with PBS. Fifty microliters of Laemmli buffer was added to the samples, which were then vortexed, boiled, eluted, boiled again, and loaded onto a polyacrylamide gel, which was transferred to nitrocellulose, and the image developed with an ECL kit ( Amersham, Piscataway, NJ ).
For MAP kinase activity analysis, cells were harvested as above and analyzed with antibodies against total and phosphorylated Erk (New England Biolabs, Beverly, MA ).
Nucleotide pool / NAD analysis
Cells were harvested, counted, pelleted, and homogenized in 0.2 N perchloric acid (PCA ). The supernatant was removed, neutralized with 0.6 N potassium hydroxide, and stored at À 208C until use. For NAD analysis, samples were analyzed on a C18 column, eluted at 1 mL / min with a 20-minute linear gradient of 1.4% methanol in 150 mM potassium phosphate (pH 6.0 ). Appropriate standards for NAD were analyzed also, and the retention time under these conditions was approximately 15 minutes. For nucleotide analysis, including cyclic GMP ( cGMP ) cells were harvested by the same procedure, but HPLC analysis utilized a strong anion exchange column eluted by a 1-hour linear gradient of 0.01 M sodium phosphate ( pH 3.5 ) to 0.5 M sodium phosphate +0.5 M potassium chloride ( pH 3.5), in a procedure previously validated. 18 
Polymerase activity
Polymerases were isolated by harvesting cells and resuspending the pellet with 10 mM KPO 4 , 2 mM DTT, 2 mM EDTA, 1 mM PMSF, 10% glycerol, and 10 g /mL each of leupeptin and pepstatin. The suspension was subjected to three cycles of freeze -thaw, followed by centrifugation and separation on DEAE cellulose. Samples were then dialyzed ( MW 12,000 -14,000 ), centrifuged, and separated on a DNA cellulose column. Polymerase samples were assayed within 24 hours of isolation. The protein content was determined by Bradford assay, and those fractions containing protein were dialyzed overnight against 50 mM Tris (pH=8.0 at 378C), and the volume reduced to approximately 0.8 mL on an Amicon (Bedford, MA ) concentrator. Polymerase activity was measured by determining the incorporation of 3 Hthymidine triphosphate into newly synthesized DNA. Twenty-five milliliters of polymerase, 15 mg activated calf thymus DNA, 100 mM dATP, dGTP, and dCTP were mixed with 3 HTTP in 50 mM Tris and the reaction allowed to incubate for 15 minutes, at which time incorporation was logarithmic. The reaction was stopped by the addition of ice -cold 15% TCA. Acid -insoluble material was collected on glass fiber filters, which were washed with 30 mL of ice -cold TCA. The filters were added to 15 mL of scintillation fluid and counted on a Beckman (Columbia, MD ) scintillation counter. Percent inhibition is calculated as a function of the counts per minute (cpm ) of cells receiving experimental treatment compared to the cpm of the PA1STK Figure 6 GCV activates erk. Erk must be phosphorylated to be active. A: Shows the Western blot of phosphorylated erk ( top ) and total erk ( bottom ) for PA1STK cells untreated ( lane 1 ) and GCV -treated ( lane 2 ) for 1 hour. A time course analysis was conducted with exposure times ranging from 3 minutes to 24 hours ( data not shown ). Activation was most evident at the 1 -hour timepoint, which is shown. B: Shows the average ratio of phosphorylated erk to total erk ( which remains stable ) after addition of GCV ( four separate experiments ).
Cancer Gene Therapy cells receiving no treatment (100% ). Inhibition is reported as the differential between the cpm of the experimental polymerases and the control polymerase cpm.
DNA synthesis
PA1STK cells ( 1Â10 6 ) in log phase growth were seeded, incubated overnight, and exposed to GCV ( 0.05 M) for 24 hours, then exposed to 3 Hthymidine (1 Ci /mL ) for 24 hours. Cells were then harvested by trypsinization, counted, and centrifuged, homogenized in 1 mL of 0.2 N PCA, centrifuged, washed three times with PCA, resuspended in saline, added to 15 mL Ecolite scintillation fluid, and counted on a scintillation counter.
Results
GCV is known to inhibit viral polymerases, but its ability to inhibit mammalian polymerases has been controversial. For the present studies, cellular polymerases were isolated from PA1STK cells that were exposed to GCV in varying concentrations to determine the effects of these agents on polymerase activity. As Figure 1 shows, GCV inhibited DNA polymerase activity in these cells. The presence of aphidicolin ( APH ), which inhibits polymerase , inhibited 90% of polymerase activity, which would be expected. The addition of GCV did not inhibit this further, suggesting that the subset inhibited by these two agents is polymerase , although additional studies to inhibit other polymerases specifically would be necessary to complete this evaluation and determine whether other polymerases are inhibited.
The next study focused on determining if the inhibition of DNA polymerase was associated with inhibition of DNA synthesis. To determine whether the GCV-mediated inhibition of cellular polymerases or another process resulted in a decrease in DNA synthesis, cells were exposed to GCV and their overall DNA synthesis was measured. Figure 2 shows the average counts per minute of incorporated 3 Hthymidine relative to GCV concentration. Increasing concentrations of GCV led to higher levels of DNA inhibition. However, the inhibition was not immediate, as evidenced by the time delay of 24 -48 hours after GCV exposure (data not shown). This 24 -to 48 -hour time delay in inhibition of DNA synthesis suggests that inhibition of DNA polymerase by GCV is a late ''downstream'' event in the cytotoxic pathway. Results are reported only for PA1STK cells but were similar in DU145 STK cells as well.
DNA damage and repair was next evaluated as a potential pathway of cell death. The ability of GCV-exposed HSV-TK cells ( PA -1STK ) to excise GCV from cellular DNA was measured (Fig 3) . The rate of GCV clearance in PA1 -TK cells was evaluated by incubating the cells with 3 HGCV for 24 hours, followed by removal of the drug and washing. Twenty-four hours after drug removal, no significant amounts of GCV were excised, suggesting that the cells did not recognize this as an illegitimate base and, thus, did not activate DNA -repair systems. This finding supports the conclusion that incorporation of GCV into DNA does not directly correlate with cell killing. To determine whether exposure to GCV affected general DNA -repair processes, we evaluated expression of PARP by Western analysis. No significant change in expression occurred within 24 hours of exposure (Fig 4 ) , or with the addition of interferon alpha, which synergistically enhances GCV-mediated killing of HSV-TK -expressing cells. Interestingly, however, PA1 parent cells had a consistently lower level of PARP expression than HSV-TK -modified ones, as did DU145 parent cells. This effect appears to be specific to the HSV-TK gene itself rather than the process of genetic modification and selection, because DU145 cells modified to express the cytidine deaminase gene had similar expression as parents. The significance of this finding is unclear at this time. In the DNA recognition and repair process, PARP uses NAD as a substrate, and the depletion of NAD stores may be a sign that PARP activity is increased. 19 To determine whether the intracellular concentration of NAD was affected by exposure to GCV, PA1STK cells were exposed to GCV for various timepoints and HPLC analysis was conducted as above, with appropriate standards for NAD. Although NAD concentrations were initially decreased, they recovered within 4 hours of drug removal (Fig 5 ) , suggesting that this event was reversible. Figure 6 demonstrates MAP kinase activation in cells exposed to GCV. GCV caused an activation of Erk1/ 2 (Fig 6A ) , as measured by a ratio of phosphorylated active Erk to total Erk (Fig 6B ) . A time course evaluation of MAP kinase activation revealed that maximal Erk activation occurred 1 hour after exposure. Presumably, the GCV must be metabolized into a phosphorylated form to produce these effects, which likely accounts for the delay, relative to other systems. PD98059 caused a suppression of phospho -Erk, as expected, and this was not altered by GCV exposure. Thus, the GCV could not overcome the PD98059-induced suppression, which is consistent with the data showing that PD98059 decreases GCV-mediated cytotoxicity. Figure 7 Inhibition of the erk pathway decreases GCV toxicity. PD98059, a specific inhibitor of erk, added to cultures of PA1STK cells prevented toxicity of GCV ( 24 -hour exposure ). Addition of PD98059 was necessary before addition of GCV. Results and SD are shown for the IC 50 ( 0.05 M GCV ); similar results were obtained at higher concentrations as well. PD98059 added 24 hours after GCV had no effect nor did the addition of SB203580 ( data not shown ).
GCV added to PA1 parent cells at the same concentration had no significant effect on Erk activation. Interestingly, preliminary results suggest that overnight exposure to GCV in PA1 -STK cells resulted in a suppression of MAP kinase, which may be a rebound effect of activation or may be a general response to the cells dying. The significance of this late suppression is unclear at this time.
To determine whether inhibiting MAP kinase activation would also inhibit GCV-mediated cytotoxicity, the inhibitor for the Erk pathway PD98059 was added to cultures of PA1, PA1 STK, DU145, and DU145 STK cells. When PD98059 was added to the culture before or concurrently with the GCV, it significantly reduced the toxicity of GCV (Fig 7 ) . If added 24 hours after GCV, it had no effect, suggesting that the earlier activation was necessary for the cytotoxicity. SB203580, which inhibits the p38 pathway, had no effect on toxicity (data not shown).
The addition of exogenous nucleotides can affect the intracellular pools of nucleotide triphosphates. To determine whether the pools were affected in PA1 -TK cells, the cells were exposed to GCV for 24 hours, precipitated in 0.2 N PCA, and the cytoplasmic fraction was analyzed by HPLC. Figure 8 shows that after 24 hours of GCV exposure, some minor disruptions in the triphosphate pools were observed. The values remained between 50% and 250% of normal, which suggests that these changes are not likely to be cytotoxic alone.
Discussion
The HSV-TK gene therapy system has shown some promise as a cancer therapy, but improvements will be necessary for it to be curative. Although some combination therapies involving this system have suggested that it can be improved, a better understanding of its mechanism of action will provide pathways that can be specifically targeted.
These studies correlating GCV toxicity with MAP kinase provide a novel potential mechanism of action for GCV in the HSV-TK system. In addition to the use of GCV in this system, these results also have implications as a general model for understanding the mechanism of action of nucleoside analogs and perhaps other antiviral agents that are being tested as anticancer therapeutics. Targeting the signaling pathways of cell death may be one method for improving their killing of tumor cells.
Evidence that Erk activation is involved in cytoprotection has been demonstrated, but its role in cytotoxicity has also become a focus of its analysis. Interestingly, its role in activation -induced cell death in T cells may be a consequence of a secondary upregulation of FasL expression, 14 which may implicate another pathway to target for enhancing tumoricidal activity in the HSV-TK system.
Our studies suggest that unlike many nucleoside analogs, GCV does not directly damage DNA or activate general repair enzymes. PARP activation has been shown to be involved in response to DNA damage in multiple systems (reviewed in Refs. 19, 20 ). The present studies show that exposure to GCV produced no significant change in PARP activity, which provides further evidence that this NA does not act as a DNA -damaging agent. The decrease in NAD levels may be a result of the observed decrease in ATP levels, however. Interestingly, PARP has been implicated in other studies to function in later stages of cell killing rather than induction of apoptosis. 21 We did observe inhibition of DNA synthesis, but not until after overnight exposure to the drug. In fact, cells often doubled before DNA synthesis inhibition, suggesting that inhibition was not an early event. The GCV-induced inhibition of DNA synthesis was likely a result of a decrease in polymerase activity. These findings support other studies showing that effects of GCV on DNA synthesis were minimal and not likely to be directly related to cytotoxicity and that GCV remained stably incorporated into other cell types as well. 22, 23 These events all occurred at a later timepoint than MAP kinase activation, and appear to be downstream results. Further, the cytotoxicity of GCV appears to be a direct result of Erk activation because it can be diminished significantly by the addition of PD98059, which specifically blocks MEK 1 activation, which is necessary for phosphorylation and activation of Erk.
The addition of exogenous nucleotides can have an effect on regulation of intracellular nucleotide pools, and some evidence suggests that depletion of specific nucleotides can enhance the cytotoxicity of drugs. 24 To determine whether the addition of GCV resulted in a disruption of nucleotide pools, we measured the intracellular concentration of ATP, CTP, GTP, and TTP. All four nucleotide pools were somewhat altered 24 hours after GCV had been added to the cultures. The difference in nucleotide pools may not be sufficiently significant to be related to cell death or could alternatively be a generalized response to cells beginning to undergo apoptosis. Because the nucleotide pools are increased at one toxic dose and decreased at another, it does not seem likely that the elevation is the causative event of cell death in this system, however, although we cannot exclude the possibility that a general disruption of nucleotide pools is involved.
The focus of these investigations has been primarily on developing GCV as a model system for studying nucleoside analog -induced tumor cell death; these studies are being extended to include the enhancement of GCVmediated toxicity by IFN, which we and others have demonstrated.
In summary, we have demonstrated a potential novel mechanism by which GCV may be toxic to cells. These findings have implications both for identifying cellular targets to improve the efficacy of GCV-based tumor therapy and for analyzing more general mechanisms of nucleoside analog action.
